Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 20;7(19):e009807. doi: 10.1161/JAHA.118.009807

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Diagnostic accuracy of anti‐Xa activity testing. Left: Scatter plots showing the correlation of FXa inhibitor concentrations (A, rivaroxaban; B, apixaban) determined by UPLC‐MS/MS, criterion standard and calibrated anti‐Xa activity testing. Green dots represent samples correctly identified as below or above the safe‐for‐treatment threshold of 30 ng/mL (true‐negative and true‐positive results). Red dots represent samples incorrectly identified as below the safe‐for‐treatment threshold (false negative). Orange dots represent samples incorrectly identified as above the safe‐for‐treatment threshold (false positive). Right: Bland‐Altman blot of UPLC‐MS/MS and anti‐Xa activity results showing the mean measurement error and SD of test results. UPLC‐MS/MS indicates ultraperformance liquid chromatography–tandem mass spectrometry.